See more : R&R Real Estate Investment Trust (RRRUF) Income Statement Analysis – Financial Results
Complete financial analysis of Visgeneer Inc. (4197.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Visgeneer Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Qinqin Foodstuffs Group (Cayman) Company Limited (1583.HK) Income Statement Analysis – Financial Results
- Energem Resources Inc. (ENMFF) Income Statement Analysis – Financial Results
- Home Consortium Limited (HMC.AX) Income Statement Analysis – Financial Results
- Avitar, Inc. (AVTI) Income Statement Analysis – Financial Results
- MGC Pharmaceuticals Limited (MGCLF) Income Statement Analysis – Financial Results
Visgeneer Inc. (4197.TWO)
About Visgeneer Inc.
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, bacterial fermentation, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cream, day cream, wrinkle cream, repairing cream, whitening cream, exfoliating cream, toner, and lotions; functional essences; body lotion and spa clay mask; physical blocker, chemical blocker, and comprehensive sun protection; face wash, wash cream, cleaning cleansing mousse, cleaning cleansing gel, shampoo, and body wash; hand cream, knee cream, foot mask, hand mask, and glucosamine cream; anti-acne cream, female private cleaning lotion, skin care, skin capsules, and hair capsules; and customized skin care products. In addition, the company offers eBmonitor Blood Monitoring System, CoreSence Skincare, BOWIL Skincare, and ZeaSight EU Patent Zeaxanthin, as well as contract manufacturing services. Visgeneer Inc. was founded in 2005 and is based in Hsinchu City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 147.99M | 157.96M | 165.29M | 175.96M | 151.99M |
| Cost of Revenue | 80.51M | 90.64M | 98.02M | 113.71M | 114.55M |
| Gross Profit | 67.48M | 67.33M | 67.27M | 62.25M | 37.44M |
| Gross Profit Ratio | 45.60% | 42.62% | 40.70% | 35.38% | 24.63% |
| Research & Development | 25.42M | 25.37M | 26.05M | 23.15M | 24.35M |
| General & Administrative | 28.60M | 26.38M | 27.08M | 27.32M | 28.88M |
| Selling & Marketing | 14.43M | 11.91M | 10.90M | 12.73M | 15.66M |
| SG&A | 43.03M | 38.29M | 37.98M | 40.04M | 43.41M |
| Other Expenses | 0.00 | 11.08M | 196.00K | 821.00K | 0.00 |
| Operating Expenses | 67.48M | 63.65M | 64.03M | 63.19M | 67.23M |
| Cost & Expenses | 169.15M | 154.29M | 162.05M | 176.90M | 181.79M |
| Interest Income | 1.66M | 494.00K | 168.00K | 374.00K | 845.00K |
| Interest Expense | 3.38M | 2.90M | 2.30M | 2.89M | 2.80M |
| Depreciation & Amortization | 17.18M | 19.19M | 15.56M | 20.42M | 19.84M |
| EBITDA | 973.00K | 34.44M | 19.19M | 20.89M | -8.23M |
| EBITDA Ratio | 0.66% | 21.80% | 11.59% | 11.75% | -6.90% |
| Operating Income | -21.16M | 15.25M | 3.60M | 256.00K | -30.32M |
| Operating Income Ratio | -14.30% | 9.65% | 2.18% | 0.15% | -19.95% |
| Total Other Income/Expenses | 1.57M | -2.90M | -2.27M | -2.68M | -1.43M |
| Income Before Tax | -19.59M | 12.35M | 1.33M | -2.43M | -31.76M |
| Income Before Tax Ratio | -13.24% | 7.82% | 0.80% | -1.38% | -20.89% |
| Income Tax Expense | 0.00 | 0.00 | 508.00K | -3.03M | 0.00 |
| Net Income | -19.59M | 12.35M | 820.00K | 603.00K | -31.76M |
| Net Income Ratio | -13.24% | 7.82% | 0.50% | 0.34% | -20.89% |
| EPS | -0.65 | 0.41 | 0.03 | 0.02 | -1.05 |
| EPS Diluted | -0.65 | 0.41 | 0.03 | 0.02 | -1.05 |
| Weighted Avg Shares Out | 30.18M | 30.18M | 30.18M | 30.18M | 30.18M |
| Weighted Avg Shares Out (Dil) | 30.18M | 30.18M | 30.18M | 30.18M | 30.18M |
Source: https://incomestatements.info
Category: Stock Reports